Decision support tools for fatty liver disease
Part of Digestive system clinical trials.
This study tests electronic tools to help doctors identify and care for patients with steatotic liver disease (fatty liver). If you have risk factors like diabetes or elevated liver enzymes, this trial may help improve your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have an upcoming or recent clinic visit (in person or by video)
- You have fatty liver disease (seen on imaging) plus at least one heart or metabolic risk factor, or you have had high liver enzymes for more than 6 months, or you have prediabetes or diabetes, or you have 2 or more heart or metabolic risk factors
- You have not had an organ transplant
- You have not seen a liver specialist in the last 3 years
- You do not have an active cancer diagnosis, alcohol-related conditions, or are pregnant or receiving palliative care
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This study tests whether adding a liver stiffness measurement to a lifestyle program helps people with MASLD (a type of fatty liver disease) improve their liver health. It is designed for people who have fatty liver and at least one sign of metabolic syndrome, like high blood pressure or diabetes.
This trial tests a new treatment called ALN-CIDEB for adults with a liver condition called MASLD, where fat builds up in the liver. The treatment aims to reduce liver fat and improve liver health.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
This study tests a new device called LiverScope® that scans your liver to detect fatty liver disease (MASLD). The scan uses special imaging technology and may help doctors diagnose liver disease more quickly and accurately.
This study tests a new screening tool to find advanced liver scarring in people with liver disease linked to diabetes. It helps doctors decide who needs more tests or specialist care.
Hear when a new MASLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.